Ratings 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Delayed Nasdaq Other stock markets 03:45:05 2024-05-02 pm EDT			5-day change	1st Jan Change
26.32 ^USD	+3.68%		+11.77%	+29.81%

Apr. 15	Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target	MT
Apr. 15	RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company's "enterprise value to sales" ratio is among the highest in the world.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
4D MOLECULAR THERAPEUTICS, INC.	+30.26%	1.3B	C-
MODERNA, INC.	+25.64%	42.68B	B-
IQVIA HOLDINGS INC.	-2.82%	42.4B	B
LONZA GROUP AG	+45.32%	40.04B	A
CELLTRION, INC.	-6.20%	28.31B	C
ICON PUBLIC LIMITED COMPANY	+7.62%	24.94B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.09%	18.96B	B
MEDPACE HOLDINGS, INC.	+29.48%	12.3B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.78%	11.95B	C+
BIO-TECHNE CORPORATION	-1.62%	11.55B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes